Survival in end stage renal disease: Calcium carbonate vs. sevelamer

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 6, 2007, Pages 617-624

  Borzecki, A M ^a,b   Lee, A ^a,b,c,d   Wang, S W ^a   Brenner, L ^e   Kazis, L E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d Sungkyunkwan University   (South Korea)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic; Phosphate binders; Renal dialysis; Renal failure; Survival

Indexed keywords

CALCIUM CARBONATE; SEVELAMER;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; VETERAN;

ADULT; AGED; CALCIUM CARBONATE; COHORT STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYAMINES; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 36248939650     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00871.x     Document Type: Article

References (20)

1. Sarnak MJ, Levey AS (1999) Epidemiology of cardiac disease in dialysis patients. Seminars in Dialysis, 12, 69 76.
2. Block GA, Hulbert-Shearon TE, Levin NW et al. (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Disease, 31, 607 617.
3. Delmez JA, Tindira CA, Windus DW et al. (1992) Calcium acetate as a phosphorus binder in hemodialysis patients. Journal of the American Society of Nephrology, 3, 96 102.
4. Bleyer AJ, Burke SK, Dillon M et al. (1999) A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Disease, 33, 694 701.
5. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International, 62, 245 252.
6. Block GA, Raggi P, Bellasi A et al. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International, 71, 438 441.
7. Hynes DM (2006) VA Health Services Research & Development completed studies: cost and effectiveness of end stage renal disease care. Available at: http://www.hsrd.research.va.gov/research/abstracts/ECI_20-016.htm, Accessed 1 March 2006.
8. Edward JH Jr. (2004) VIReC Research User Guide: VHA Decision Support System Clinical National Data Extracts FY2001-2003. VA Hospital, Hines, IL : Veterans Affairs Information Resource Center, May 2004.
9. VIReC Research User Guide: FY2002 VHA Medical SAS Outpatient Datasets. Available at: http://www.virec.research.va.gov/References/RUG/RUG-Outpatient02. pdf, Accessed 1 December 2005.
10. Smith MW, Chow A (2006) Fee Basis Data: A Guide for Researchers. HERC Technical Report ##18. Available at: http://www.herc.research.gov/files/RPRT- 412.pdf.
11. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology, 45, 613 619.
12. Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. The American Statistician, 39, 33 38.
13. Borzecki AM, Wong AT, Hickey EC et al. (2004) Identifying hypertension-related comorbidities from administrative data: what's the optimal approach? American Journal of Medical Quality, 19, 201 206.
14. Suki W, Zabaneh R, Cangiano J, et al. (2005) The DCOR trial? A Prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. Renal Week, November 8-13, 2005 Philadelphia, PA. Abstract TH-PO745.
15. Collins AJ, St Peter WL, Dalleska FW et al. (2000) Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clinical Nephrology, 54, 334 341.
16. Lowrie EG, Lew NL. (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. American Journal of Kidney Disease, 15, 458 482.
17. Ma JZ, Ebben J, Xia H et al. (1999) Hematocrit level and associated mortality in hemodialysis patients. Journal of the American Society of Nephrology, 10, 610 619.
18. Xia H, Ebben J, Ma JZ et al. (1999) Hematocrit levels and hospitalization risks in hemodialysis patients. Journal of the American Society of Nephrology, 10, 1309 1316.
19. Besarab A, Bolton WK, Browne JK et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine, 339, 584 590.
20. Wanner C, Krane V, Marz W et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine, 353, 238 248.